Taysha Gene Therapies announced executive leadership changes effective immediately. Taysha’s Chair of the Board of Directors, Sean P. Nolan, a highly experienced biopharmaceutical industry senior leader, has been appointed Chief Executive Officer, succeeding RA Session II, who has resigned from his operating role, but will continue to serve on the Company’s Board of Directors. In addition, Sukumar Nagendran, M.D., a Director on Taysha’s Board of Directors, and an accomplished physician, drug developer, and biotech executive, has been appointed President and Head of R&D. "I am excited to join the Company at such a dynamic time in our journey and energized to work with the team to expedite progress on our two lead clinical programs in Giant Axonal Neuropathy (GAN) and Rett syndrome, as well as further strengthen our strategic partnership with Astellas," said Mr. Nolan. "2023 is a crucial year for Taysha and it is imperative that we precisely execute as an organization on delivering key clinical and regulatory milestones as we endeavor to bring transformative therapies to patients and families suffering from devastating diseases."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies Announces Executive Leadership Changes
- Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit
- Taysha Gene Therapies price target lowered to $14 from $20 at Wells Fargo
- Taysha Gene Therapies price target lowered to $15 from $25 at BTIG
- Taysha Gene Therapies downgraded to Neutral from Buy at Goldman Sachs